Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

BACKGROUND: A nivolumab monotherapy flat-dosing regimen of 480 mg every 4 weeks (Q4W) has been approved in several markets, including the United States, Canada, and European Union, as an alternative dosing regimen for several indications. Approvals of this Q4W regimen were based on population pharma...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Ann Oncol
Main Authors: Long, G V, Tykodi, S S, Schneider, J G, Garbe, C, Gravis, G, Rashford, M, Agrawal, S, Grigoryeva, E, Bello, A, Roy, A, Rollin, L, Zhao, X
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2018
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6290887/
https://ncbi.nlm.nih.gov/pubmed/30215677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy408
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker